Windtree Announces Istaroxime has been Chosen for a Plenary Session Presentation at the Heart Failure Society of America 2025
MWN-AI** Summary
Windtree Therapeutics, Inc. has announced that its investigational drug istaroxime is set to be featured in a plenary session at the Heart Failure Society of America’s (HFSA) Annual Scientific Meeting in 2025. The presentation will highlight interim data from the Phase 2 study examining istaroxime for patients with SCAI Stage C cardiogenic shock, a condition associated with a significant in-hospital mortality rate ranging between 20% to 30%.
Istaroxime has shown promise in addressing acute decompensated heart failure, a therapeutic area that has experienced a lack of innovation in recent years. The data from this interim analysis, which included the first 20 patients enrolled, reveals that istaroxime’s effects align with those observed in prior studies, offering Windtree the confidence to advance toward a global Phase 3 trial.
Noteworthy aspects of istaroxime include its dual-action mechanism that enhances cardiac function—improving systolic and diastolic function—without triggering a rise in heart rate or causing statistically significant arrhythmias. This positions istaroxime as a potentially pivotal advancement for patients suffering from low blood pressure due to heart failure and related complications, such as renal function impairment and fluid overload.
Jed Latkin, CEO of Windtree, expressed optimism regarding the interim results, underscoring the significant unmet medical need in treating acute heart failure conditions that have been overlooked for decades. With istaroxime's favorable safety profile and clinical effects, Windtree is poised to create a meaningful impact in this critical therapeutic area. As the company actively seeks development partners for its therapeutic pipelines, the upcoming HFSA presentation is anticipated to garner attention from the medical community and potential investors alike.
MWN-AI** Analysis
Windtree Therapeutics, Inc. (NASDAQ: WINT) recently garnered attention after announcing that istaroxime will be presented at the upcoming Heart Failure Society of America 2025 annual meeting. This meeting is crucial for the company as it showcases the interim data from its Phase 2 SEISMiC C study of istaroxime in patients experiencing SCAI Stage C cardiogenic shock, a condition with a concerning in-hospital mortality rate of 20-30%. The early results indicate that istaroxime may significantly improve cardiac function and blood pressure without adversely affecting heart rate or increasing arrhythmias, which are common concerns in heart failure treatments.
For investors, this development presents a unique opportunity, especially given the historical lack of innovation in the treatment of acute decompensated heart failure and cardiogenic shock. With Windtree's emphasis on advancing istaroxime to a global Phase 3 trial, confidence in its long-term potential appears strong. The favorable safety profile and the lack of new safety concerns in the interim data enhance the viability of istaroxime as a therapeutic option, positioning Windtree strategically within a high-need market.
Investors should consider the broader implications of this announcement, including the potential for partnerships and collaborations that could accelerate istaroxime's development and commercialization. Additionally, monitoring upcoming presentations and analyst feedback is crucial in assessing the stock's trajectory.
Overall, Windtree’s stock could benefit from heightened investor interest leading up to and following the presentation at the HFSA meeting. Given the promising interim results, market participants may wish to assess their positions in Windtree while keeping a close eye on forthcoming clinical data and strategic developments.
**MWN-AI Summary and Analysis is based on asking OpenAI to summarize and analyze this news release.
Presentation will be the interim data from the Phase 2 study of istaroxime in SEISMiC C - Cardiogenic Shock SCAI Stage C
Cardiogenic shock SCAI Stage C has an in hospital mortality rate of 20-30%
Istaroxime interim data was consistent with the profile seen in previous studies gives Windtree confidence to move forward with a global Phase 3 study
WARRINGTON, Pa., Aug. 11, 2025 (GLOBE NEWSWIRE) -- Windtree Therapeutics, Inc. (“Windtree” or the “Company”) (NasdaqCM: WINT), a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners, announced that istaroxime was chosen for a presentation entitled, “Safety and Efficacy of intravenous administration of istaroxime for 48 hours in patients with SCAI Stage C cardiogenic shock due to heart failure” at the Heart Failure Society of America (HFSA) Annual Scientific Meeting 2025.
Acute decompensated heart failure and cardiogenic shock have had very little drug innovation in decades. The Company believes istaroxime has a profile that offers potential benefits to patients with low blood pressure due to heart failure. Istaroxime improves cardiac function and can increase blood pressure without increasing heart rate. Also, istaroxime tends to preserve measures of renal function and contributes to resolution of congestion and fluid overload that often accompanies heart failure. Importantly, it does not appear to increase clinically significant arrythmias. The istaroxime cardiogenic shock SCAI Stage C interim analysis included the first 20 patients enrolled in the study. There were no new safety concerns identified, and no apparent excess arrythmias in patients treated with istaroxime when given with standard of care therapies. The effects on hemodynamic and echocardiographic measures appeared to be consistent with results seen in previous istaroxime studies.
“We are very pleased with the interim results of the SEISMiC C study,” said Jed Latkin, Chief Executive Officer of Windtree. “We believe istaroxime can be an important drug innovation for acute decompensated heart failure and cardiogenic shock patients because the istaroxime studies have promising results and this is a condition with a large unmet need and has been underserved for decades.”
About Istaroxime
Istaroxime is a first-in-class dual-mechanism therapy designed to improve both systolic and diastolic cardiac function. Istaroxime is a positive inotropic agent that increases myocardial contractility through inhibition of Na+/K+- ATPase with a complimentary mechanism that facilitates myocardial relaxation through activation of the SERCA2a calcium pump on the sarcoplasmic reticulum enhancing calcium reuptake from the cytoplasm. Data from multiple Phase 2 studies in patients with early cardiogenic shock or acute decompensated heart failure demonstrate that istaroxime infused intravenously can significantly improve cardiac function and blood pressure without increasing heart rate or the incidence of clinically significant cardiac rhythm disturbances.
About Windtree Therapeutics, Inc.
Windtree Therapeutics, Inc. is a diversified company with several divisions, including a cryptocurrency treasury strategy and two promising therapeutic pipelines for which the Company is actively seeking long-term development partners.
Forward Looking Statements
The Company may, in some cases, use terms such as “predicts,” “believes,” “potential,” “proposed,” “continue,” “estimates,” “anticipates,” “expects,” “plans,” “intends,” “may,” “could,” “might,” “will,” “should,” or other words that convey uncertainty of future events or outcomes to identify these forward-looking statements. Such statements are based on information available to the Company as of the date of this press release and are subject to numerous important factors, risks, and uncertainties that may cause actual events or results to differ materially from the Company’s current expectations. Examples of such risks and uncertainties include, among other things: the success of the SEISMiC C Study, the ability to move istaroxime to a global Phase 3 program and risks related to the Company’s ability to manage costs and execute on its operational and budget plans. These and other risks are described in the Company’s periodic reports, including its Annual Report on Form 10-K, Quarterly Reports on Form 10-Q, and Current Reports on Form 8-K, filed with or furnished to the Securities and Exchange Commission and available at www.sec.gov. Any forward-looking statements that the Company makes in this press release speak only as of the date of this press release. The Company assumes no obligation to update forward-looking statements whether as a result of new information, future events, or otherwise, after the date of this press release.
Contact Information:
Eric Curtis
ecurtis@windtreetx.com
FAQ**
How does Windtree Therapeutics Inc. WINT plan to address the significant in-hospital mortality rate of 20-30% in patients with SCAI Stage C cardiogenic shock during its upcoming Phase 3 study?
Can Windtree Therapeutics Inc. WINT provide more details on the patient demographics and baseline characteristics from the SEISMiC C interim analysis that may impact the efficacy of istaroxime?
What specific strategies does Windtree Therapeutics Inc. WINT intend to implement to manage operational costs and ensure successful progression from Phase 2 to Phase 3 for istaroxime?
How does Windtree Therapeutics Inc. WINT assess the long-term implications of the promising results seen in interim data, particularly in relation to regulatory approvals and market competition?
**MWN-AI FAQ is based on asking OpenAI questions about Windtree Therapeutics Inc. (NASDAQ: WINT).
NASDAQ: WINT
WINT Trading
-12.12% G/L:
$0.116 Last:
1,921,610 Volume:
$0.132 Open:
